Plexymer, Inc.

Plexymer, Inc. is a biotechnology company that operates an AI-driven, robotic self-driving lab to modernize and streamline the formulation of biologics, specifically focusing on custom polymer excipients for therapeutic proteins. Founded in 2021 by Adam Gormley and Matthew Tamasi based on technology developed at Rutgers University, the company utilizes a closed-loop platform that integrates automated combinatorial polymer chemistry with machine learning. This technology autonomously designs, synthesizes, and tests polymers to identify the optimal chemical structure for stabilizing proteins. By replacing slow, manual, and conventional scientific workflows with an automated system, the company aims to expedite the research and development process for complex therapeutics.

Operating as a contract research organization, Plexymer serves the biopharmaceutical industry by assisting researchers in developing more stable antibody therapies that can withstand less delicate storage conditions. Its services and platform help customers address critical challenges in protein formulation, including reducing development timelines and lowering material usage for sensitive biological products. The company’s approach is designed to enhance efficiency in the discovery pipeline, providing specialized expertise in material design and biopharmaceutical development for clients ranging from academic researchers to commercial pharmaceutical organizations.